Search results for "Cirrhosis"
Urinary biomarker may help predict cirrhosis outcomes, study finds
Levels of urine liver fatty acid-binding protein could be used together with Model for End-stage Liver Disease scoring to improve predictions of liver failure or death, according to an analysis of patients hospitalized for decompensated cirrhosis.
https://gastroenterology.acponline.org/archives/2021/09/24/3.htm
24 Sep 2021
Biopsy-proven NAFLD associated with higher rates of MACE
Patients in a Swedish study whose nonalcoholic fatty liver disease (NAFLD) was confirmed on biopsy were more likely to experience incident major adverse cardiovascular events (MACE).
https://gastroenterology.acponline.org/archives/2021/09/24/2.htm
24 Sep 2021
In decompensated cirrhosis, targeted albumin infusions did not improve an in-hospital composite outcome at 15 days
The results of this randomized trial should not discourage clinicians from using albumin for recognized indications, but they do not support targeting an arbitrary serum albumin level, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2021/08/27/7.htm
27 Aug 2021
Treatment algorithm updated for chronic HBV
The recommendations address use of newer therapies and are intended to offer guidance on treating chronic hepatitis B virus (HBV) infection while additional antiviral agents are in development.
https://gastroenterology.acponline.org/archives/2021/08/27/1.htm
27 Aug 2021
COVID-19 mRNA vaccines appear effective in patients with cirrhosis
A retrospective cohort study compared outcomes among U.S. veterans with cirrhosis who received at least one dose of an mRNA COVID-19 vaccine with those of a propensity-matched control group of unvaccinated patients at similar risk.
https://gastroenterology.acponline.org/archives/2021/07/23/1.htm
23 Jul 2021
In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy
Results from a French trial provide the best available evidence to justify using the expensive antibiotic in patients with hepatic encephalopathy associated with transjugular intrahepatic portosystemic shunt, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2021/07/23/7.htm
23 Jul 2021
FDA restricts use of liver disease drug in certain patients
The agency added new warnings to the prescribing information for obeticholic acid, including a contraindication in patients with primary biliary cholangitis and advanced cirrhosis.
https://gastroenterology.acponline.org/archives/2021/06/25/7.htm
25 Jun 2021
MKSAP Quiz: Dyspnea in a patient with liver disease
A 48-year-old woman with cirrhosis due to primary biliary cholangitis reports shortness of breath of six weeks' duration. Her oxygen saturation is 98% while supine, but it drops to 92% with standing. What is the most appropriate diagnostic test?
https://gastroenterology.acponline.org/archives/2021/05/28/5.htm
28 May 2021
MKSAP Quiz: Management of HBV infection
This month's quiz asks readers to determine the most appropriate next step in management of a 29-year-old woman with hepatitis B virus (HBV) infection and normal liver enzyme levels.
https://gastroenterology.acponline.org/archives/2021/04/23/4.htm
23 Apr 2021
Antibiotic may prevent hepatic encephalopathy after TIPS in patients with cirrhosis
A French trial found that 34% of patients who received rifaximin before and after placement of a transjugular intrahepatic portosystemic shunt (TIPS) had hepatic encephalopathy versus 53% of those who received placebo, with no differences in adverse events or transplant-free survival.
https://gastroenterology.acponline.org/archives/2021/02/26/7.htm
26 Feb 2021